Dissecting Tumor Heterogeneity by Liquid Biopsy—A Comparative Analysis of Post-Mortem Tissue and Pre-Mortem Liquid Biopsies in Solid Neoplasias
Authors:
- Tatiana MögeleTMTatiana Mögele
- Kathrin HildebrandKHKathrin Hildebrand
- Aziz SultanASAziz Sultan
- Sebastian SommerSSSebastian Sommer
- Lukas RentschlerLRLukas Rentschler
- Maria KlingMKMaria Kling
- Irmengard SaxISIrmengard Sax
- Matthias SchlesnerMSMatthias Schlesner
- Bruno MärklBruno Märkl
- Martin TrepelMTMartin Trepel
- Maximilian SchmutzMSMaximilian Schmutz
- Rainer ClausRCRainer Claus
Open Access
- 6 August 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7614
Abstract
Tumor heterogeneity encompasses genetic, epigenetic, and phenotypic diversity, impacting treatment response and resistance. Spatial heterogeneity occurs both inter- and intra-lesionally, while temporal heterogeneity results from clonal evolution. High-throughput technologies like next-generation sequencing (NGS) enhance tumor characterization, but conventional biopsies still do not adequately capture genetic heterogeneity. Liquid biopsy (LBx), analyzing circulating tumor DNA (ctDNA), provides a minimally invasive alternative, offering real-time tumor evolution insights and identifying resistance mutations overlooked by tissue biopsies. This study evaluates the capability of LBx to capture tumor heterogeneity by comparing genetic profiles from multiple metastatic lesions and LBx samples. Eight patients from the Augsburger Longitudinal Plasma Study with various types of cancer provided 56 postmortem tissue samples, which were compared against pre-mortem LBx-derived circulating-free DNA sequenced by NGS. Tissue analyses revealed significant mutational diversity (4–12 mutations per patient, VAFs: 1.5–71.4%), with distinct intra- and inter-lesional heterogeneity. LBx identified 51 variants (4–17 per patient, VAFs: 0.2–31.1%), which overlapped with mutations from the tissue samples by 33–92%. Notably, 22 tissue variants were absent in LBx, whereas 18 LBx-exclusive variants were detected (VAFs: 0.2–2.8%). LBx effectively captures tumor heterogeneity, but should be used in conjunction with tissue biopsies for comprehensive genetic profiling.Keywords
Funding Information
- Intramural funding program (ALPS trial) of the Faculty of Medicine, University of Augsburg
This publication has 54 references indexed in Scilit:
- Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trialAnnals of Oncology, 2024
- Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA SequencingCell, 2020
- Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsyMolecular Oncology, 2020
- Clinical implications of intratumor heterogeneity: challenges and opportunitiesJournal of Molecular Medicine, 2020
- Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinomaInternational Journal of Cancer, 2019
- Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung CancerJAMA Oncology, 2019
- Genomic Evolution of Breast Cancer Metastasis and RelapseCancer Cell, 2017
- Measuring cancer evolution from the genomeThe Journal of Pathology, 2016
- The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional samplingCancer Medicine, 2014
- The significance of biological heterogeneityCancer and Metastasis Reviews, 1990